GlassScriptPhysician profile
Megan M Chambers
NPI 1154632198
$2,960.81
in general payments reported to CMS, 2019-2025
28 companies · $729 in 2025
The $729 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $207 · 2021: $458 · 2022: $384 · 2023: $247 · 2024: $526 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,501.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $411.05 | 2019-2025 | Rocklatan, Acrysof Iq Panoptix Uv Iol, Clareon |
| Aerie Pharmaceuticals, INC. | $309.27 | 2019-2021 | |
| New World Medical,INC. | $259.57 | 2021-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Bausch & Lomb Americas INC. | $254.43 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Abbvie INC. | $251.86 | 2022-2025 | Botox, Xen Glaucoma Treatment System, Alphagan P |
| Biotissue Holdings INC. | $185.09 | 2020-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $181.34 | 2019-2021 | |
| Dompe US, INC. | $151.73 | 2024-2025 | Oxervate |
| Glaukos Corporation | $116.35 | 2022-2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished), Istent Infinite |
| Novartis Pharmaceuticals Corporation | $111.11 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $93.22 | 2020-2025 | |
| Allergan, INC. | $91.09 | 2019-2022 | |
| Amgen INC. | $76.42 | 2024-2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $69.56 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $66.03 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $49.79 | 2022-2025 | Ryzumvi, Tyrvaya |
| Harrow Eye, LLC | $38.97 | 2025 | Triesence |
| Sight Sciences, INC. | $36.10 | 2024 | Omni Surgical System |
| Tarsus Pharmaceuticals, INC. | $35.92 | 2025 | Xdemvy |
| Ani Pharmaceuticals, INC. | $30.03 | 2025 | Purified Cortrophin Gel |
| Ocular Therapeutix, INC. | $25.69 | 2020-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $21.81 | 2024 | Tecnis Iol |
| Tearlab Corp | $20.11 | 2020 | |
| Rxsight INC | $19.60 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Ivantis, INC | $16.72 | 2021 | |
| Thea Pharma INC. | $15.61 | 2025 | Iyuzeh |
| Shire North American Group INC | $11.25 | 2019 | |
| Merz Pharmaceuticals, LLC | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Chambers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.